These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 24743285)

  • 1. [A case of breast cancer with repeated cardiac dysfunction due to trastuzumab].
    Tokuda A; Abe H; Kawai Y; Umeda T; Tomida K; Mori T; Cho H; Kubota Y; Tani T
    Gan To Kagaku Ryoho; 2014 Mar; 41(3):365-7. PubMed ID: 24743285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
    Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O
    Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
    Joensuu H; Bono P; Kataja V; Alanko T; Kokko R; Asola R; Utriainen T; Turpeenniemi-Hujanen T; Jyrkkiö S; Möykkynen K; Helle L; Ingalsuo S; Pajunen M; Huusko M; Salminen T; Auvinen P; Leinonen H; Leinonen M; Isola J; Kellokumpu-Lehtinen PL
    J Clin Oncol; 2009 Dec; 27(34):5685-92. PubMed ID: 19884557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study.
    Sawaki M; Mukai H; Tokudome N; Nakayama T; Taira N; Mizuno T; Yamamoto Y; Horio A; Watanabe T; Uemura Y; Ohashi Y
    Breast Cancer; 2012 Jul; 19(3):253-8. PubMed ID: 21526424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer.
    Tarantini L; Cioffi G; Gori S; Tuccia F; Boccardi L; Bovelli D; Lestuzzi C; Maurea N; Oliva S; Russo G; Faggiano P;
    J Card Fail; 2012 Feb; 18(2):113-9. PubMed ID: 22300778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
    Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
    Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
    Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
    J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of adjuvant trastuzumab-associated cardiac toxicity in korean patients with breast cancer: a single-center analysis.
    Cha C; Ahn SG; Lee HM; Lee HW; Lee SA; Jeong J
    Oncology; 2013; 85(4):228-34. PubMed ID: 24081024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
    Joensuu H; Kellokumpu-Lehtinen PL; Bono P; Alanko T; Kataja V; Asola R; Utriainen T; Kokko R; Hemminki A; Tarkkanen M; Turpeenniemi-Hujanen T; Jyrkkiö S; Flander M; Helle L; Ingalsuo S; Johansson K; Jääskeläinen AS; Pajunen M; Rauhala M; Kaleva-Kerola J; Salminen T; Leinonen M; Elomaa I; Isola J;
    N Engl J Med; 2006 Feb; 354(8):809-20. PubMed ID: 16495393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.
    Pernas S; Gil-Gil M; de Olza MO; Gumà A; Climent F; Petit A; Pla MJ; García-Tejedor A; López-Ojeda A; Falo C; Fernandez-Otega A; Mesia C; Pérez-Martin FJ; Urruticoechea A; Germà JR
    Breast Cancer Res Treat; 2012 Aug; 134(3):1161-8. PubMed ID: 22772380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
    Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G
    J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cardiotoxicity of trastuzumab of significance in the adjuvant treatment of breast cancer].
    Menke-van der Houven van Oordt CW; Fliervoet HJ; Mandigers CM; van Spronsen DJ
    Ned Tijdschr Geneeskd; 2008 Jan; 152(3):158-63. PubMed ID: 18271465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
    Andreopoulou E; Gaiotti D; Kim E; Volm M; Oratz R; Freedberg R; Downey A; Vogel CL; Chia S; Muggia F
    Clin Breast Cancer; 2007 Aug; 7(9):690-6. PubMed ID: 17919349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
    Suter TM; Procter M; van Veldhuisen DJ; Muscholl M; Bergh J; Carlomagno C; Perren T; Passalacqua R; Bighin C; Klijn JG; Ageev FT; Hitre E; Groetz J; Iwata H; Knap M; Gnant M; Muehlbauer S; Spence A; Gelber RD; Piccart-Gebhart MJ
    J Clin Oncol; 2007 Sep; 25(25):3859-65. PubMed ID: 17646669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial.
    Roca L; Diéras V; Roché H; Lappartient E; Kerbrat P; Cany L; Chieze S; Canon JL; Spielmann M; Penault-Llorca F; Martin AL; Mesleard C; Lemonnier J; de Cremoux P
    Breast Cancer Res Treat; 2013 Jun; 139(3):789-800. PubMed ID: 23780683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
    Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
    J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial.
    Untch M; Eidtmann H; du Bois A; Meerpohl HG; Thomssen Ch; Ebert A; Harbeck N; Jackisch C; Heilman V; Emons G; Wallwiener D; Wiese W; Blohmer JU; Höffken K; Kuhn W; Reichardt P; Muscholl M; Pauschinger M; Langer B; Lück HJ
    Eur J Cancer; 2004 May; 40(7):988-97. PubMed ID: 15093573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.
    Cardinale D; Colombo A; Torrisi R; Sandri MT; Civelli M; Salvatici M; Lamantia G; Colombo N; Cortinovis S; Dessanai MA; Nolè F; Veglia F; Cipolla CM
    J Clin Oncol; 2010 Sep; 28(25):3910-6. PubMed ID: 20679614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.
    Kelly H; Kimmick G; Dees EC; Collichio F; Gatti L; Sawyer L; Ivanova A; Dressler L; Graham ML; Carey LA
    Clin Breast Cancer; 2006 Aug; 7(3):237-43. PubMed ID: 16942640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.
    Spielmann M; Roché H; Delozier T; Canon JL; Romieu G; Bourgeois H; Extra JM; Serin D; Kerbrat P; Machiels JP; Lortholary A; Orfeuvre H; Campone M; Hardy-Bessard AC; Coudert B; Maerevoet M; Piot G; Kramar A; Martin AL; Penault-Llorca F
    J Clin Oncol; 2009 Dec; 27(36):6129-34. PubMed ID: 19917839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.